Compare · NVO vs QTTB
NVO vs QTTB
Side-by-side comparison of Novo Nordisk A/S (NVO) and Q32 Bio Inc. (QTTB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and QTTB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 443.5x QTTB ($485.8M).
- Over the past year, NVO is down 12.1% and QTTB is up 782.4% - QTTB leads by 794.5 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 4 for QTTB).
- NVO has more recent analyst coverage (25 ratings vs 14 for QTTB).
- Company
- Novo Nordisk A/S
- Q32 Bio Inc.
- Price
- $48.65+3.65%
- $16.28-0.31%
- Market cap
- $215.46B
- $485.8M
- 1M return
- -2.08%
- +7.18%
- 1Y return
- -12.07%
- +782.38%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 4
- Recent ratings
- 25
- 14
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest QTTB
- Morgan Stanley initiated coverage on Q32 Bio with a new price target
- SEC Form 10-Q filed by Q32 Bio Inc.
- Q32 Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Q32 Bio Inc.
- SEC Form EFFECT filed by Q32 Bio Inc.
- SEC Form 424B3 filed by Q32 Bio Inc.
- Amendment: SEC Form 4 filed by Director Tzianabos Arthur
- Amendment: SEC Form 4 filed by Director Laporte Kathleen
- Amendment: SEC Form 4 filed by Director Lundberg Sven Ante